Novo Nordisk Preps Obesity Drug

Danish drug maker Novo Nordisk said it expects to file for U.S. regulatory approval for its new obesity drug "within weeks," in a bid to diversify a product portfolio that is focused on diabetes treatments.



from WSJ.com: US Business http://online.wsj.com/article/SB10001424052702304579404579236032260796574.html?mod=pls_whats_news_us_business_f

via IFTTT